Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study

• Status: Enrolling by invitation
• Trial end date: 2033-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a long-term follow up study evaluating the safety of BPX-501 T cells (rivogenlecleucel) and infused in pediatric patients previously enrolled on the BP-004 study.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bellicum Pharmaceuticals

Criteria

Inclusion Criteria:

• Signed written informed consent by the patient or the patient's guardian for children who are minors

• Enrolled on BP-004 protocol, received BPX-501 infusion, completed or discontinued from the study, and are beyond Day +180.

Exclusion Criteria:

• Lack of parents'/guardian's informed consent for children who are minors

• Loss of allograft prior to 6 months